Jiang H, Xi H, Juhas M, Zhang Y
Front Bioeng Biotechnol. 2022; 9:797831.
PMID: 34976987
PMC: 8714947.
DOI: 10.3389/fbioe.2021.797831.
Kapoor A, Jones M, Shafer R, Rhee S, Kazanjian P, Delwart E
J Virol. 2004; 78(13):7112-23.
PMID: 15194787
PMC: 421662.
DOI: 10.1128/JVI.78.13.7112-7123.2004.
Arch Dis Child. 2001; 84(3):230-6.
PMID: 11207172
PMC: 1718689.
DOI: 10.1136/adc.84.3.230.
Frost S, Nijhuis M, Schuurman R, Boucher C, Brown A
J Virol. 2000; 74(14):6262-8.
PMID: 10864635
PMC: 112131.
DOI: 10.1128/jvi.74.14.6262-6268.2000.
Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C
J Clin Microbiol. 1999; 37(7):2291-6.
PMID: 10364600
PMC: 85140.
DOI: 10.1128/JCM.37.7.2291-2296.1999.
Managing resistance to anti-HIV drugs: an important consideration for effective disease management.
Vandamme A, Van Laethem K, De Clercq E
Drugs. 1999; 57(3):337-61.
PMID: 10193687
DOI: 10.2165/00003495-199957030-00006.
HIV drug resistance: genotypic assays and their possible applications.
Ballard A, Cane P, Pillay D
Sex Transm Infect. 1999; 74(4):243-8.
PMID: 9924461
PMC: 1758134.
DOI: 10.1136/sti.74.4.243.
Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.
Lewis J, Balfe P, Arnold C, Kaye S, Tedder R, McKeating J
J Virol. 1998; 72(11):8943-51.
PMID: 9765439
PMC: 110311.
DOI: 10.1128/JVI.72.11.8943-8951.1998.
Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis.
Descamps D, Calvez V, Collin G, Cecille A, Apetrei C, Damond F
J Clin Microbiol. 1998; 36(7):2143-5.
PMID: 9650987
PMC: 105012.
DOI: 10.1128/JCM.36.7.2143-2145.1998.
Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.
Tedder R, Kaye S, Loveday C, Weller I, Jeffries D, Norman J
J Clin Microbiol. 1998; 36(4):1056-63.
PMID: 9542937
PMC: 104689.
DOI: 10.1128/JCM.36.4.1056-1063.1998.
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
Hertogs K, De Bethune M, Miller V, Ivens T, Schel P, van Cauwenberge A
Antimicrob Agents Chemother. 1998; 42(2):269-76.
PMID: 9527771
PMC: 105399.
DOI: 10.1128/AAC.42.2.269.
Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.
Edelstein R, Nickerson D, Tobe V, Frenkel L
J Clin Microbiol. 1998; 36(2):569-72.
PMID: 9466779
PMC: 104580.
DOI: 10.1128/JCM.36.2.569-572.1998.
Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.
Muir P, Kammerer U, Korn K, Mulders M, Poyry T, Weissbrich B
Clin Microbiol Rev. 1998; 11(1):202-27.
PMID: 9457433
PMC: 121380.
DOI: 10.1128/CMR.11.1.202.
A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.
Shi C, Mellors J
Antimicrob Agents Chemother. 1998; 41(12):2781-5.
PMID: 9420060
PMC: 164210.
DOI: 10.1128/AAC.41.12.2781.
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase.
Keulen W, Back N, van Wijk A, Boucher C, Berkhout B
J Virol. 1997; 71(4):3346-50.
PMID: 9060708
PMC: 191477.
DOI: 10.1128/JVI.71.4.3346-3350.1997.
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.
Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C
Antimicrob Agents Chemother. 1997; 41(2):284-91.
PMID: 9021181
PMC: 163703.
DOI: 10.1128/AAC.41.2.284.
An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker D, Tachedjian G, Solomon A, Gurusinghe A, Land S, Birch C
J Virol. 1996; 70(11):8010-8.
PMID: 8892925
PMC: 190874.
DOI: 10.1128/JVI.70.11.8010-8018.1996.
Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.
Shafer R, Winters M, Mayers D, Japour A, Kuritzkes D, Weislow O
J Clin Microbiol. 1996; 34(7):1849-53.
PMID: 8784610
PMC: 229135.
DOI: 10.1128/JCM.34.7.1849-1853.1996.
Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.
Goudsmit J, de Ronde A, Ho D, Perelson A
J Virol. 1996; 70(8):5662-4.
PMID: 8764084
PMC: 190530.
DOI: 10.1128/JVI.70.8.5662-5664.1996.
Antimicrobial agent resistance in mycobacteria: molecular genetic insights.
Musser J
Clin Microbiol Rev. 1995; 8(4):496-514.
PMID: 8665467
PMC: 172873.
DOI: 10.1128/CMR.8.4.496.